Tuberous Sclerosis Complex

Overview

Tuberous sclerosis complex (TSC) is a rare, multisystem genetic disorder that causes non-cancerous (benign) tumors called hamartomas to grow in many different parts of the body. These tumors can affect the brain, skin, kidneys, heart, lungs, and other organs, leading to a wide variety of symptoms that can range from mild to severe. The condition affects approximately 1 in 6,000 to 10,000 births worldwide and occurs in all races and ethnic groups equally.

TSC is caused by mutations in either the TSC1 or TSC2 gene, which normally help regulate cell growth and division. When these genes are mutated, cells can grow and divide uncontrollably, forming the characteristic tumors of TSC. The condition follows an autosomal dominant inheritance pattern, meaning that only one copy of the abnormal gene is needed to cause the disorder. However, about two-thirds of cases result from new mutations, with no family history of the condition.

The severity and specific manifestations of TSC vary greatly among individuals, even within the same family. Some people may have only mild skin abnormalities, while others may experience severe neurological involvement including seizures, intellectual disability, and behavioral problems. This variability makes TSC a challenging condition to diagnose and manage, requiring a multidisciplinary approach to care throughout the patient's lifetime.

Symptoms

The symptoms of tuberous sclerosis complex vary widely depending on which organs are affected and the size and location of the tumors. Manifestations can appear at any age, from infancy through adulthood, and may change over time. The condition's hallmark is the combination of symptoms affecting multiple organ systems, particularly the brain, skin, and kidneys.

Neurological Symptoms

Seizures are the most common neurological manifestation, affecting up to 90% of individuals with TSC. They often begin in infancy as infantile spasms, a specific type of seizure that can lead to developmental delays if not treated promptly. Various seizure types may occur, including focal seizures, generalized tonic-clonic seizures, and complex partial seizures. Early recognition and treatment are crucial for optimal outcomes.

Skin Manifestations

Skin abnormalities are present in nearly all individuals with TSC and are often the first noticeable signs:

• Hypomelanotic macules (ash leaf spots): Light-colored patches that may be present at birth
• Facial angiofibromas: Small red bumps on the face, appearing in childhood
• Shagreen patches: Thick, rough patches of skin, usually on the lower back
• Forehead plaques: Raised, discolored areas on the forehead
• Ungual fibromas: Growths around or under the nails

Brain Manifestations

Brain involvement is common and can include:

• Cortical tubers: Hamartomas in the cerebral cortex causing seizures and developmental delays
• Subependymal nodules (SENs): Small tumors along the ventricle walls
• Subependymal giant cell astrocytomas (SEGAs): Larger tumors that can block cerebrospinal fluid flow
• White matter abnormalities: Affecting brain connectivity and function

Behavioral and Cognitive Symptoms

TSC-associated neuropsychiatric disorders (TAND) affect most individuals and include:

• Autism spectrum disorder (40-50% of patients)
• Intellectual disability (45-60% of patients)
• Attention deficit hyperactivity disorder (ADHD)
• Depression and anxiety
• Sleep disorders
• Aggressive behaviors

Other Organ System Involvement

Causes

Tuberous sclerosis complex is caused by mutations in one of two genes: TSC1 (located on chromosome 9) or TSC2 (located on chromosome 16). These genes provide instructions for making proteins called hamartin (TSC1) and tuberin (TSC2), which work together to help regulate cell growth and division. When either gene is mutated, this regulatory function is disrupted, leading to uncontrolled cell growth and tumor formation.

Genetic Mechanisms

The TSC1 and TSC2 genes function as tumor suppressor genes through the following mechanism:

• Normal function: Hamartin and tuberin form a protein complex that inhibits mTOR (mechanistic target of rapamycin), a key regulator of cell growth
• When mutated: The protein complex cannot properly inhibit mTOR, leading to increased cell growth and proliferation
• Two-hit hypothesis: Although TSC is inherited in a dominant pattern, tumors typically form when both copies of the gene are affected in a cell

Inheritance Patterns

TSC can be inherited or occur as a new mutation:

• Inherited cases (33%): One parent has TSC and passes the mutated gene to their child
• De novo mutations (67%): The mutation occurs spontaneously in the egg or sperm cell, or early in embryonic development
• Autosomal dominant: Only one mutated copy of the gene is needed to cause the condition
• 50% chance: Each child of an affected parent has a 50% chance of inheriting TSC

Mosaicism

Some individuals have mosaic TSC, where only some cells carry the mutation:

• Results from mutations occurring after fertilization
• May cause milder symptoms
• Can be difficult to detect with standard genetic testing
• Still carries risk of transmission to offspring if germline cells are affected

Genotype-Phenotype Correlations

While both TSC1 and TSC2 mutations cause the same condition, some differences exist:

• TSC2 mutations: Generally associated with more severe symptoms, including higher rates of intellectual disability and kidney involvement
• TSC1 mutations: Often result in milder disease, though significant overlap exists
• No mutation identified (10-15%): Some individuals meet clinical criteria but no mutation is found with current testing methods

Risk Factors

The primary risk factor for tuberous sclerosis complex is having a family history of the condition. However, since most cases result from new mutations, many affected individuals have no family history. Understanding risk factors helps with genetic counseling and early detection strategies.

Genetic Risk Factors

• Family history: Having a parent with TSC confers a 50% risk
• Advanced paternal age: Slightly increased risk of de novo mutations
• Germline mosaicism: Unaffected parents may carry mutations in some reproductive cells
• Previous affected child: Parents of a child with de novo TSC have a 1-2% recurrence risk due to possible mosaicism

Factors Affecting Severity

While TSC occurrence is primarily genetic, several factors may influence disease severity:

• Type of mutation: TSC2 mutations often cause more severe disease
• Location of mutation: Certain mutation types may affect protein function differently
• Genetic modifiers: Other genes may influence symptom severity
• Environmental factors: May affect tumor growth and complications
• Early intervention: Prompt treatment of seizures may improve developmental outcomes

Reproductive Considerations

For individuals with TSC or at risk:

• Genetic counseling: Recommended before pregnancy
• Prenatal testing: Available through amniocentesis or chorionic villus sampling
• Preimplantation genetic diagnosis: Option for couples using IVF
• Pregnancy risks: Women with TSC face increased risks, especially with kidney or lung involvement

Diagnosis

Diagnosing tuberous sclerosis complex requires a comprehensive evaluation combining clinical criteria, imaging studies, and genetic testing. The diagnosis can be challenging due to the variable presentation and age-dependent manifestations. Updated diagnostic criteria help ensure accurate and timely diagnosis.

Clinical Diagnostic Criteria

The 2012 International Tuberous Sclerosis Complex Consensus Conference established criteria based on major and minor features:

Major Features

1. Hypomelanotic macules (≥3, at least 5mm diameter)
2. Angiofibromas (≥3) or fibrous cephalic plaque
3. Ungual fibromas (≥2)
4. Shagreen patch
5. Multiple retinal hamartomas
6. Cortical dysplasias (includes tubers and white matter lines)
7. Subependymal nodules
8. Subependymal giant cell astrocytoma
9. Cardiac rhabdomyoma
10. Lymphangioleiomyomatosis (LAM)
11. Angiomyolipomas (≥2)

Minor Features

1. "Confetti" skin lesions
2. Dental enamel pits (≥3)
3. Intraoral fibromas (≥2)
4. Retinal achromic patch
5. Multiple renal cysts
6. Nonrenal hamartomas

Definitive Diagnosis Requires:

• Two major features, OR
• One major feature plus two minor features, OR
• Identification of a pathogenic TSC1 or TSC2 mutation

Imaging Studies

Brain Imaging

• MRI: Preferred for detecting cortical tubers, SENs, SEGAs, and white matter abnormalities
• CT scan: May show calcified subependymal nodules
• EEG: Essential for evaluating seizures and epilepsy

Abdominal Imaging

• MRI or CT: For detecting renal angiomyolipomas and cysts
• Ultrasound: Initial screening tool for kidney lesions

Cardiac Evaluation

• Echocardiogram: For detecting cardiac rhabdomyomas
• Fetal echocardiography: Can detect cardiac tumors prenatally

Other Imaging

• Chest CT: For women to screen for LAM
• Ophthalmologic examination: For retinal hamartomas
• Dermatologic evaluation: Wood's lamp examination for hypomelanotic macules

Genetic Testing

Molecular genetic testing can identify mutations in TSC1 or TSC2:

• Sequence analysis: Detects small mutations
• Deletion/duplication analysis: Identifies larger genetic changes
• Detection rate: 85-90% in individuals meeting clinical criteria
• Mosaic mutations: May require testing multiple tissue types

Prenatal Diagnosis

When a parent has TSC or a pathogenic mutation is known:

• Fetal ultrasound: May detect cardiac rhabdomyomas or brain abnormalities
• Fetal MRI: More sensitive for brain lesions
• Genetic testing: Through amniocentesis or chorionic villus sampling

Treatment Options

Treatment of tuberous sclerosis complex requires a multidisciplinary approach tailored to each individual's specific manifestations. Management focuses on controlling symptoms, preventing complications, and improving quality of life. The introduction of mTOR inhibitors has revolutionized treatment by targeting the underlying molecular pathway.

Seizure Management

Seizure control is often the most critical aspect of TSC management:

Medical Management

• Vigabatrin: First-line treatment for infantile spasms in TSC
• Other antiepileptic drugs: Chosen based on seizure type and individual response
• mTOR inhibitors: Everolimus approved as adjunctive therapy for partial-onset seizures
• Cannabidiol: May be considered for drug-resistant epilepsy

Surgical Options

• Epilepsy surgery: For focal seizures not controlled with medication
• Vagus nerve stimulation: For medically refractory epilepsy
• Ketogenic diet: May help some patients with difficult-to-control seizures

mTOR Inhibitors

These medications target the underlying molecular abnormality in TSC:

Everolimus (Afinitor)

• FDA-approved for SEGAs, renal angiomyolipomas, and seizures
• Can shrink tumors and reduce seizure frequency
• Requires regular monitoring for side effects
• Effects may be reversible if medication is stopped

Sirolimus

• Used for various TSC manifestations, particularly LAM
• Topical formulation for facial angiofibromas
• May stabilize lung function in LAM

Organ-Specific Treatments

Brain Tumors (SEGAs)

• mTOR inhibitors: First-line for growing SEGAs
• Surgical resection: For symptomatic tumors or those not responding to medication
• Regular monitoring: MRI surveillance for all patients

Kidney Manifestations

• Angiomyolipomas <4cm: Active surveillance
• Angiomyolipomas >4cm: mTOR inhibitors or embolization
• Nephron-sparing surgery: When possible for large or bleeding tumors
• Blood pressure management: Important for kidney health

Skin Lesions

• Topical sirolimus: For facial angiofibromas
• Laser therapy: For angiofibromas and forehead plaques
• Surgical excision: For problematic ungual fibromas
• Sun protection: Important for all skin manifestations

Lung Disease (LAM)

• Sirolimus: May stabilize lung function decline
• Bronchodilators: For airflow obstruction
• Pulmonary rehabilitation: To maintain function
• Lung transplantation: For end-stage disease
• Estrogen avoidance: May accelerate LAM progression

Behavioral and Cognitive Interventions

• Early intervention programs: For developmental delays
• Special education services: Tailored to individual needs
• Behavioral therapy: For autism spectrum behaviors and ADHD
• Psychotropic medications: For anxiety, depression, or aggression
• Sleep hygiene: Important for seizure control and behavior

Supportive Care

• Regular surveillance: Following published guidelines for monitoring
• Genetic counseling: For family planning
• Dental care: Regular monitoring for enamel pits and oral fibromas
• Ophthalmologic care: Annual eye exams
• Transition planning: From pediatric to adult care

Prevention

While tuberous sclerosis complex cannot be prevented in individuals who inherit or develop mutations in the TSC1 or TSC2 genes, several strategies can help prevent complications and optimize outcomes. For families affected by TSC, genetic counseling and prenatal options are available.

Primary Prevention

For families with a history of TSC:

• Genetic counseling: Essential before pregnancy to understand risks and options
• Prenatal diagnosis: Available when a parent has TSC or the family mutation is known
• Preimplantation genetic diagnosis (PGD): Allows selection of unaffected embryos during IVF
• Donor gametes: An option for some families to avoid transmission

Secondary Prevention - Early Detection

For individuals with TSC, preventing complications through surveillance:

Recommended Surveillance Schedule

• Brain MRI: Every 1-3 years to monitor for SEGAs
• Renal imaging: Every 1-3 years for angiomyolipomas and cysts
• Pulmonary function tests: Baseline at age 18 for females
• Annual assessments: Skin, teeth, eyes, blood pressure
• EEG: As indicated for seizure management
• Neuropsychological evaluation: Baseline and as needed

Complication Prevention

Preventing Seizure-Related Complications

• Early recognition and treatment of infantile spasms
• Medication adherence for seizure control
• Avoiding seizure triggers (sleep deprivation, stress)
• Safety measures (supervision during bathing, avoiding heights)

Preventing Kidney Complications

• Regular monitoring of angiomyolipoma size
• Early intervention for growing lesions
• Blood pressure control
• Avoiding nephrotoxic medications when possible
• Hydration and healthy lifestyle

Preventing Lung Complications (for women)

• Baseline pulmonary function testing
• Avoiding exogenous estrogen
• Smoking cessation
• Pneumococcal and influenza vaccinations
• Early treatment of respiratory infections

Lifestyle Modifications

• Sun protection: To prevent worsening of skin lesions
• Regular exercise: Within safe limits, avoiding contact sports if at risk
• Healthy diet: Supporting overall health and development
• Stress management: Can help with seizure control and behavior
• Education: Understanding TSC helps with self-advocacy and compliance

Family Planning Considerations

For individuals with TSC considering pregnancy:

• Pre-pregnancy counseling with specialists
• Medication review and optimization
• Assessment of maternal risks (kidney, lung, cardiac function)
• Planning for increased surveillance during pregnancy
• Discussion of inheritance risks and testing options

When to See a Doctor

Individuals with tuberous sclerosis complex require regular medical care and should maintain close contact with their healthcare team. However, certain symptoms require immediate attention, while others warrant prompt scheduling of appointments.

Seek Emergency Care Immediately For:

• New onset seizures or significant change in seizure pattern
• Severe, sudden headache (may indicate SEGA growth or bleeding)
• Vision changes or eye pain
• Difficulty breathing or chest pain (possible LAM complication)
• Severe abdominal or back pain (possible kidney bleeding)
• Blood in urine (hematuria)
• Signs of increased intracranial pressure (vomiting, lethargy, confusion)
• Sudden weakness or numbness

Schedule Urgent Appointment For:

• Increasing frequency or severity of seizures despite medication
• New or worsening behavioral problems
• Rapid growth of skin lesions
• Progressive shortness of breath with exertion
• Persistent abdominal discomfort
• Unexplained weight loss or fatigue
• Side effects from medications

Regular Follow-up Needed For:

• Routine surveillance imaging as recommended
• Medication monitoring and adjustments
• Developmental assessments
• Preventive care and vaccinations
• Transition from pediatric to adult care
• Family planning discussions

For Newly Diagnosed Individuals:

Initial comprehensive evaluation should include:

• Complete physical and neurological examination
• Baseline imaging studies (brain MRI, renal imaging, echocardiogram)
• Ophthalmologic examination
• Developmental or cognitive assessment
• Genetic counseling and testing
• Referrals to appropriate specialists

Related Conditions

Understanding conditions related to tuberous sclerosis complex helps with differential diagnosis and recognizing overlapping features. Some conditions share similar genetic mechanisms or clinical manifestations.

Other Neurocutaneous Syndromes

• Neurofibromatosis type 1 - Another disorder with skin and nervous system tumors
• Von Hippel-Lindau disease - Multiple organ tumors
• Sturge-Weber syndrome - Facial birthmarks and seizures

Other mTOR Pathway Disorders

• PTEN hamartoma syndrome - Multiple hamartomas
• Proteus syndrome - Overgrowth and hamartomas
• Focal cortical dysplasia type II - Isolated brain malformation

Conditions with Similar Features

• Epilepsy - Various causes of seizures
• Autism spectrum disorder - Common in TSC
• Polycystic kidney disease - Multiple kidney cysts
• Sporadic LAM - Can occur without TSC

Differential Diagnoses

• Multiple cafe-au-lait spots - Consider neurofibromatosis
• Isolated angiofibromas - May be sporadic
• Renal cell carcinoma - Different from angiomyolipomas
• Cardiac tumors - Rhabdomyomas are specific to TSC in children

Frequently Asked Questions

What is the life expectancy for someone with TSC?

Life expectancy varies greatly depending on the severity of symptoms. Many individuals with mild TSC have normal lifespans. However, those with severe neurological involvement, uncontrolled epilepsy, or significant organ complications may have shortened life expectancy. Early diagnosis and proper management have significantly improved outcomes.

Can TSC skip generations?

No, TSC cannot skip generations because it's an autosomal dominant condition. However, the severity can vary greatly between family members, and some individuals may have such mild symptoms that they go undiagnosed. This can create the appearance of skipping generations.

Are all children with TSC intellectually disabled?

No, approximately 40-50% of individuals with TSC have normal intelligence. The risk of intellectual disability is higher in those with early-onset seizures, particularly infantile spasms. Early seizure control and intervention can improve cognitive outcomes.

Can TSC be cured?

Currently, there is no cure for TSC. However, many symptoms can be effectively managed with medications, surgery, and supportive care. mTOR inhibitors represent a targeted treatment that addresses the underlying molecular cause, though effects may be reversible if treatment stops.

Is it safe for women with TSC to become pregnant?

Many women with TSC can have successful pregnancies, but careful planning and monitoring are essential. Risks depend on organ involvement, particularly kidney and lung function. Pre-pregnancy counseling with specialists is crucial to assess individual risks and optimize management.

How often should someone with TSC have medical check-ups?

The frequency depends on age and specific manifestations. Generally, annual comprehensive evaluations are recommended, with organ-specific imaging every 1-3 years. More frequent visits may be needed for active issues like poorly controlled seizures or growing tumors.

Can adults develop TSC symptoms for the first time?

While TSC is present from birth, some manifestations may not appear until adulthood. For example, LAM typically develops in women during their reproductive years, and some kidney tumors grow slowly over time. Adults diagnosed with TSC often had subtle childhood symptoms that were overlooked.

References

1. Northrup H, Aronow ME, Bebin EM, et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol. 2021;123:50-66.
2. Henske EP, Jóźwiak S, Kingswood JC, et al. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016;2:16035.
3. Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015;14(7):733-745.
4. Franz DN, Belousova E, Sparagana S, et al. Everolimus for treatment of tuberous sclerosis complex: Final results from EXIST-3. PLoS One. 2018;13(6):e0197358.
5. Kingswood JC, Belousova E, Benedik MP, et al. Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness. Nephrol Dial Transplant. 2019;34(3):502-508.
6. de Vries PJ, Whittemore VH, Leclezio L, et al. Tuberous Sclerosis Associated Neuropsychiatric Disorders (TAND) and the TAND Checklist. Pediatr Neurol. 2015;52(1):25-35.
7. McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. Am J Respir Crit Care Med. 2016;194(6):748-761.